Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab von Benson, Jacqueline M, Sachs, Clifford W, Treacy, George, Zhou, Honghui, Pendley, Charles E, Brodmerkel, Carrie M, Shankar, Gopi, Mascelli, Mary A

Volltext

Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization von LINCOFF, A. Michael, KEREIAKES, Dean J, MASCELLI, Mary A, DECKELBAUM, Lawrence I, BARNATHAN, Elliot S, PATEL, Kamlesh K, FREDERICK, Bart, NAKADA, Marian T, TOPOL, Eric J

Volltext

An Additional Mechanism of Action of Abciximab: Dispersal of Newly Formed Platelet Aggregates von Marciniak, Stanley J., Mascelli, Mary A., Furman, Mark I., Michelson, Alan D., Jakubowski, Joseph A., Jordan, Robert E., Marchese, Peter J, Frelinger, Andrew L.

Volltext

Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade von MASCELLI, M. A, LANCE, E. T, DAMARAJU, L, WAGNER, C. L, WEISMAN, H. F, JORDAN, R. E, PHD

Volltext

Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy von MASCELLI, M. A, WORLEY, S, VERIABO, N. J, LANCE, E. T, MACK, S, SCHAIBLE, T, WEISMAN, H. F, JORDAN, R. E

Volltext

High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: Results from TIMI (Thr... von COULTER, S. A, CANNON, C. P, BARNATHAN, E. S, BRAUNWALD, E, KLEIMAN, N. S, AULT, K. A, ANTMAN, E. M, DE WERF, F. V, ADGEY, A. A. J, GIBSON, C. M, GIUGLIANO, R. P, MASCELLI, M. A, SCHERER, J

Volltext

Effect of Ca2+ Chelation on the Platelet Inhibitory Ability of the GPIIb/IIIa Antagonists Abciximab, Eptifibatide and Tirofiban von Marciniak, Stanley J., Jordan, Robert E., Mascelli, Mary A.

Volltext

Pharmacodynamics of abciximab during angioplasty: Comparison to healthy subjects von Abernethy, Darrell R., Pezzullo, John, Mascelli, Mary A., Frederick, Bart, Kleiman, Neal S., Freedman, Jane

Volltext

Abciximab Pharmacodynamic Model with Neural Networks used to Integrate Sources of Patient Variability von Urquidi‐Macdonald, Mirna, Mager, Donald E., Mascelli, Mary A., Frederick, Bart, Freedman, Jane, Fitzgerald, Desmond J., Kleiman, Neal S., Abernethy, Darrell R.

Volltext

Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications von COHEN, Sidney A, TRIKHA, Mohit, MASCELLI, Mary A

Volltext

Abciximab partially attenuates adverse events associated with trombocytopenia: analysis of GUSTO IV ACS von Williams, Richard T., Sane, David C., Damaraju, Lakshmi V., Mascelli, Mary A., Barnathan, Elliot S., Califf, Robert M., Simoons, Maarten

Volltext

Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects von Freedman, Jane, Mascelli, Mary A., Pezzullo, John C., Barnathan, Elliot S., Frederick, Bart, Jordan, Robert E., Abernethy, Darrell R.

Volltext

Analysis of GPIIb/IIIa Receptor Number by Quantification of 7E3 Binding to Human Platelets von Wagner, Carrie L., Mascelli, Mary A., Neblock, Donald S., Weisman, Harlan F., Coller, Barry S., Jordan, Robert E.

Volltext

Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets von Wagner, CL, Mascelli, MA, Neblock, DS, Weisman, HF, Coller, BS, Jordan, RE

Volltext

Effect of Ca Chelation on the Platelet Inhibitory Ability of the GPIIb/IIIa Antagonists Abciximab, Eptifibatide and Tirofiban von Stanley J. Marciniak, Robert E. Jordan, Mary A. Mascelli

Volltext

Ig H and L chain contributions to autoimmune specificities von Radic, MZ, Mascelli, MA, Erikson, J, Shan, H, Weigert, M

Volltext

Proteolytic studies on the structure of bovine von Willebrand factor von Mascelli, Mary A, Kirby, Edward P

Volltext

Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab von Mascelli, Mary A., Kleiman, Neal S., Marciniak, Stanley J., Damaraju, Lakshmi, Weisman, Harlan F., Jordan, Robert E.

Volltext

Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: Ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions von Kleiman, Neal S., Grazeiadei, Nikki, Maresh, Kelly, Taylor, Rebecca J., Frederick, Bart, Lance, Ellen T., Effron, Mark B., Jordan, Robert E., Mascelli, Mary A.

Volltext

Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab von Prystowsky, Eric N., Mascelli, Mary A., Kleiman, Neal S., Marciniak, Stanley J., Damaraju, Lakshmi J., Weisman, Harlan F.

Volltext